Failure of Oral Valganciclovir Treatment in Congenital Cytomegalovirus Hepatitis in a Neonate

Abstract

Get full access to this article

View all access options for this article.

References

Swanson

Schliess

MR.

Congenital cytomegalovirus infection: new prospects for prevention and therapy. Pediatr Clin North Am. 2013;60:335-349.

Hamilton

van Zuylen

Shand

. Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: a systematic review. Rev Med Virol. 2014;24:420-433.

Kimberlin

Jester

Sánchez

PJ.

Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372:933-943.

Acosta

Brundage

King

. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther. 2007;81:867-872.

Marshall

Koch

WC.

Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events. Paediatr Drugs. 2009;11:309-321.

Kadambari

Williams

Luck

Griffiths

Sharland

Evidence based management guidelines for the detection and treatment of congenital CMV. Early Hum Dev. 2011;87:723-728.

Choi

Sharon

Balfour

Jr Belani

Pozos

Schleiss

MR.

Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection. J Clin Virol. 2013;57:356-360.

Campanini

Zavattoni

Cristina

Gazzolo

Stronati

Baldanti

Multiple ganciclovir-resistant strains in a newborn with symptomatic congenital human cytomegalovirus infection. J Clin Virol. 2012;54:86-88.

Kampmann

Schindele

Apelt

. Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection. Med Microbiol Immunol. 2011;200:109-113.